Advanced search
Publication Cover
Acta Orthopaedica Volume 92, 2021 - Issue 4
Journal homepage
2,100
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Proton-pump inhibitors are associated with increased risk of prosthetic joint infection in patients with total hip arthroplasty: a case-cohort study

Maarten M Bruina Department of Orthopedic Surgery, HagaZiekenhuis, Den Haag;c Department of Orthopedic Surgery, LUMC, Leiden, The Netherlands
,
Ruud L M Deijkersa Department of Orthopedic Surgery, HagaZiekenhuis, Den Haag
,
Roos Bazuina Department of Orthopedic Surgery, HagaZiekenhuis, Den Haag
,
Erika P M Elzakkerb Department of Medical Microbiology, Hagaziekenhuis, Den Haag
&
Bart G Pijlsa Department of Orthopedic Surgery, HagaZiekenhuis, Den Haag;c Department of Orthopedic Surgery, LUMC, Leiden, The NetherlandsCorrespondence[email protected]
Pages 431-435 | Published online: 12 May 2021

  • Agastya G, West B C, Callahan J M. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol 2000; 22(2): 357–72.
  • Aggarwal V K, Weintraub S, Klock J, Stachel A, Phillips M, Schwarzkopf R, Iorio R, Bosco J, Zuckerman J D, Vigdorchik J M, Long W J. 2019 Frank Stinchfield Award: A comparison of prosthetic joint infection rates between direct anterior and non-anterior approach total hip arthroplasty: a single institution experience. Bone Joint J 2019; 101-B(6_Supple_B): 2–8.
  • Antonelli B, Chen A F. Reducing the risk of infection after total joint arthroplasty: preoperative optimization. Arthroplasty 2019; 1(1): 4.
  • Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity. General Pharmacology: Vascul Pharmacol 1995; 26(6): 1413–18.
  • Baek S-H. Identification and preoperative optimization of risk factors to prevent periprosthetic joint infection. WJO 2014; 5(3): 362.
  • Barlow W E, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52(12): 1165–72.
  • Cai J, Zeng D. Sample size/power calculation for case-cohort studies. Biometrics 2004; 60(4): 1015–24.
  • Choong P F M, Dowsey M M, Carr D, Daffy J, Stanley P. Risk factors associated with acute hip prosthetic joint infections and outcome of treatment with a rifampin based regimen. Acta Orthop 2007; 78(6): 755–65.
  • Cunningham R, Jones L, Enki D G, Tischhauser R. Proton pump inhibitor use as a risk factor for Enterobacteriaceal infection: a case-control study. J Hosp Infect 2018; 100(1): 60–4.
  • Dowsey M M, Choong P F M. Obesity is a major risk factor for prosthetic infection after primary hip arthroplasty. Clin Orthop Relat Res 2008; 466(1): 153–8.
  • Dunkler D, Ploner M, Schemper M, Heinze G. Weighted Cox regression using the R package coxphw. J Stat Soft 2018; 84(2).
  • Grimes D A, Schulz K F. Bias and causal associations in observational research. Lancet 2002; 359(9302): 248–52.
  • Hálfdánarson Ó Ö, Pottegård A, Björnsson E S, Lund S H, Ogmundsdottir M H, Steingrímsson E, Ogmundsdottir H M, Zoega H. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol 2018; 11: 175628481877794.
  • Hung W-T, Teng Y-H, Yang S-F, Yeh H-W, Yeh Y-T, Wang Y-H, Chou M-Y, Chou M-C, Chan C-H, Yeh C-B. Association between proton pump inhibitor use and CNS infection risk: a retrospective cohort study. JCM 2018; 7(9): 252.
  • Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil 2018; 24(2): 182–96.
  • Kunutsor S K, Whitehouse M R, Blom A W, Beswick A D, INFORM Team. Patient-related risk factors for periprosthetic joint infection after total joint arthroplasty: a systematic review and meta-analysis. PLoS ONE 2016; 11(3): e0150866.
  • Lambert A A, Lam J O, Paik J J, Ugarte-Gil C, Drummond M B, Crowell T A. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE 2015; 10(6): e0128004.
  • Lee D K. Alternatives to P value: confidence interval and effect size. Korean J Anesthesiol 2016; 69(6): 555.
  • Liu W, Baker S S, Trinidad J, Burlingame A L, Baker R D, Forte J G, Virtuoso L P, Egilmez N K, Zhu L. Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol 2013; 48(12): 1343–52.
  • Masnoon N, Shakib S, Kalisch-Ellett L, Caughey G E. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17(1): 230.
  • Parvizi J, Zmistowski B, Berbari E F, Bauer T W, Springer B D, Della Valle C J, Garvin K L, Mont M A, Wongworawat M D, Zalavras C G. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res 2011; 469(11): 2992–4.
  • Pedersen A B, Svendsson J E, Johnsen S P, Riis A, Overgaard S. Risk factors for revision due to infection after primary total hip arthroplasty: a population-based study of 80,756 primary procedures in the Danish Hip Arthroplasty Registry. Acta Orthop 2010; 81(5): 542–7.
  • Prentice R L. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986; 73(1): 1–11.
  • Pruzansky J S, Bronson M J, Grelsamer R P, Strauss E, Moucha C S. Prevalence of modifiable surgical site infection risk factors in hip and knee joint arthroplasty patients at an urban academic hospital. J. Arthroplasty 2014; 29(2): 272–6.
  • Rezapoor M, Parvizi J. Prevention of periprosthetic joint infection. J. Arthroplasty 2015; 30(6): 902–7.
  • Rothman K, Greenland S, Lash T. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
  • van Steenbergen L N, Denissen G A W, Spooren A, van Rooden S M, van Oosterhout F J, Morrenhof J W, Nelissen R G H H. More than 95% completeness of reported procedures in the population-based Dutch Arthroplasty Register: external validation of 311,890 procedures. Acta Orthop 2015; 86(4): 498–505.
  • Tande A J, Patel R. Prosthetic joint infection. Clin Microbiol Rev 2014; 27(2): 302–45.
  • Veltman E S, F D J, Nelissen R G, Poolman R W. Antibiotic prophylaxis and DAIR treatment in primary total hip and knee arthroplasty, a national survey in the Netherlands. J Bone Joint Infect 2018; 3(1): 5–9.
  • Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30(5): 1118–22.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.